CA3105585A1 - A xinafoate salt of a jak inhibiting compound - Google Patents
A xinafoate salt of a jak inhibiting compound Download PDFInfo
- Publication number
- CA3105585A1 CA3105585A1 CA3105585A CA3105585A CA3105585A1 CA 3105585 A1 CA3105585 A1 CA 3105585A1 CA 3105585 A CA3105585 A CA 3105585A CA 3105585 A CA3105585 A CA 3105585A CA 3105585 A1 CA3105585 A1 CA 3105585A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- mediated diseases
- subject
- xinafoate salt
- jak kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699955P | 2018-07-18 | 2018-07-18 | |
| US62/699,955 | 2018-07-18 | ||
| US201962866013P | 2019-06-25 | 2019-06-25 | |
| US62/866,013 | 2019-06-25 | ||
| PCT/EP2019/069252 WO2020016302A1 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3105585A1 true CA3105585A1 (en) | 2020-01-23 |
Family
ID=67396927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3105585A Pending CA3105585A1 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11149029B2 (https=) |
| EP (1) | EP3823964A1 (https=) |
| JP (2) | JP7422732B2 (https=) |
| KR (1) | KR102849420B1 (https=) |
| CN (2) | CN118580223A (https=) |
| AU (1) | AU2019304014B2 (https=) |
| BR (1) | BR112021000467A2 (https=) |
| CA (1) | CA3105585A1 (https=) |
| IL (1) | IL280025B2 (https=) |
| MA (1) | MA53162A (https=) |
| MX (1) | MX2021000611A (https=) |
| MY (1) | MY209356A (https=) |
| SG (1) | SG11202100240RA (https=) |
| WO (1) | WO2020016302A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009031011A2 (en) | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| MX2013003019A (es) * | 2010-09-15 | 2013-05-28 | Hoffmann La Roche | Compuestos de azabenzotiazol, composiciones y metodos de uso. |
| AU2014342338B2 (en) * | 2013-11-01 | 2016-12-01 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| PL3189045T3 (pl) | 2014-08-11 | 2022-04-04 | Sun Pharmaceutical Industries Limited | Nowe sole nilotynibu i jego polimorfy |
| BR112018005833B1 (pt) * | 2015-09-25 | 2023-10-10 | Dizal (Jiangsu) Pharmaceutical Co., Limited | Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto |
| KR102585048B1 (ko) | 2017-01-17 | 2023-10-05 | 아스트라제네카 아베 | Jak1 선택적 억제제 |
| CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
-
2019
- 2019-07-17 SG SG11202100240RA patent/SG11202100240RA/en unknown
- 2019-07-17 EP EP19742558.0A patent/EP3823964A1/en active Pending
- 2019-07-17 AU AU2019304014A patent/AU2019304014B2/en active Active
- 2019-07-17 CN CN202410624343.9A patent/CN118580223A/zh active Pending
- 2019-07-17 MA MA053162A patent/MA53162A/fr unknown
- 2019-07-17 MY MYPI2021000231A patent/MY209356A/en unknown
- 2019-07-17 US US16/513,781 patent/US11149029B2/en active Active
- 2019-07-17 JP JP2021502626A patent/JP7422732B2/ja active Active
- 2019-07-17 CN CN201980047093.4A patent/CN112424187B/zh active Active
- 2019-07-17 KR KR1020217001860A patent/KR102849420B1/ko active Active
- 2019-07-17 MX MX2021000611A patent/MX2021000611A/es unknown
- 2019-07-17 WO PCT/EP2019/069252 patent/WO2020016302A1/en not_active Ceased
- 2019-07-17 BR BR112021000467-0A patent/BR112021000467A2/pt unknown
- 2019-07-17 CA CA3105585A patent/CA3105585A1/en active Pending
- 2019-07-17 IL IL280025A patent/IL280025B2/en unknown
-
2023
- 2023-10-02 JP JP2023171327A patent/JP7644190B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019304014B2 (en) | 2022-08-18 |
| IL280025B1 (en) | 2024-10-01 |
| KR102849420B1 (ko) | 2025-08-25 |
| WO2020016302A1 (en) | 2020-01-23 |
| BR112021000467A2 (pt) | 2021-04-06 |
| WO2020016302A8 (en) | 2020-11-12 |
| JP2024001109A (ja) | 2024-01-09 |
| MA53162A (fr) | 2021-05-26 |
| CN112424187B (zh) | 2024-06-21 |
| IL280025A (en) | 2021-03-01 |
| AU2019304014A1 (en) | 2021-03-04 |
| SG11202100240RA (en) | 2021-02-25 |
| MY209356A (en) | 2025-07-03 |
| MX2021000611A (es) | 2021-04-13 |
| EP3823964A1 (en) | 2021-05-26 |
| CN112424187A (zh) | 2021-02-26 |
| US11149029B2 (en) | 2021-10-19 |
| KR20210033474A (ko) | 2021-03-26 |
| CN118580223A (zh) | 2024-09-03 |
| IL280025B2 (en) | 2025-02-01 |
| US20200062737A1 (en) | 2020-02-27 |
| JP7422732B2 (ja) | 2024-01-26 |
| JP7644190B2 (ja) | 2025-03-11 |
| JP2021530526A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7644190B2 (ja) | Ｊａｋ阻害化合物のキシナホ酸塩 | |
| CA2776028C (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| TWI549953B (zh) | ７－環戊基－２－（５－哌－１－基－吡啶－２－基胺基）－７ｈ－吡咯并［２，３－ｄ］嘧啶－６－羧酸二甲醯胺之鹽類及其製備方法 | |
| RU2649001C1 (ru) | Производные 2,4-дизамещенного фенилен-1,5-диамина и их применения, фармацевтические композиции и фармацевтически приемлемые композиции, полученные из них | |
| WO2021057832A1 (en) | Kras mutant protein inhibitor | |
| EP3173412B1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| US9879008B2 (en) | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof | |
| WO2016007185A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| JP2020504747A (ja) | ベンズイミダゾール誘導体、調製方法およびそれらの使用 | |
| TW202112768A (zh) | 二取代吡唑化合物 | |
| EP3768272B1 (en) | Jak inhibitors | |
| US20060079688A1 (en) | Process for producing acid adduct salt of polyacidic base compound | |
| EA044028B1 (ru) | Ксинафоатная соль соединения, ингибирующего jak | |
| JP2022528437A (ja) | ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 | |
| CN103339124A (zh) | 二(芳氨基)芳基化合物的制备方法及其合成中间体 | |
| US20240383909A1 (en) | Co-crystals | |
| CN121605107A (zh) | 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法 | |
| WO2025003769A2 (zh) | 芳杂环并吡咯烷酮类衍生物及其用途 | |
| CN119859139A (zh) | 双盐酸安罗替尼的固体形式及其制备方法 | |
| CN121449616A (zh) | 靶向降解细胞周期依赖性激酶的化合物及其制备方法、药物组合物和用途 | |
| HK40062437A (en) | Disubstituted pyrazole compounds as ketohexokinase inhbitors | |
| HK40062437B (en) | Disubstituted pyrazole compounds as ketohexokinase inhbitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240715 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240715 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250307 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250410 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250625 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250717 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250915 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251113 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260114 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260114 |